New York, New York--(Newsfile Corp. - September 2, 2025) - OS Therapies Inc. (OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology ...
Current holders of five-year warrants with a current exercise price of $1.12 per share issued in connection with PIPE transaction initially closed on December 31, 2024 (“Old Warrants”) offered ...